Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
20 nov. 2024 07h02 HE
|
Pasithea
Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
09 sept. 2024 08h01 HE
|
Pasithea
Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
03 sept. 2024 08h02 HE
|
Pasithea
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
28 août 2024 09h11 HE
|
Pasithea
Pasithea Therapeutics will present at H.C. Wainwright’s Global Investment Conference, highlighting PAS-004 development for NF1 and cancer.
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
28 mai 2024 06h59 HE
|
Pasithea
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
24 avr. 2024 07h59 HE
|
Pasithea
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
13 févr. 2024 07h59 HE
|
Pasithea
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
02 janv. 2024 08h35 HE
|
Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
28 déc. 2023 17h00 HE
|
Pasithea
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
19 déc. 2023 17h19 HE
|
Pasithea
Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)